Holen Sie sich die Stockscreener-App
20.51
2.91%
0.58
Handel nachbörslich:
20.51
Schlusskurs vom Vortag:
$19.93
Offen:
$19.9
24-Stunden-Volumen:
237.78K
Relative Volume:
0.87
Marktkapitalisierung:
$985.68M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-6.627
EPS:
-3.0949
Netto-Cashflow:
-
1W Leistung:
-15.87%
1M Leistung:
-21.81%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$19.41
$20.88
1-Wochen-Bereich:
$18.77
$25.22
52-Wochen-Spanne:
$15.10
$29.05
Odyssey Therapeutics Inc Stock (ODTX) Company Profile
Firmenname
Odyssey Therapeutics Inc
Sektor
Branche
Telefon
(212) 841-1000
Adresse
51 SLEEPER STREET, BOSTON
Compare ODTX vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ODTX
Odyssey Therapeutics Inc
|
20.51 | 985.68M | 0 | 0 | 0 | -3.0949 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Odyssey Therapeutics Inc Aktie (ODTX) Neueste Nachrichten
Top Odyssey Therapeutics (ODTX) Competitors 2026 - MarketBeat
Odyssey Therapeutics at Stifel forum: pipeline bets and cash runway By Investing.com - Investing.com Canada
Odyssey Therapeutics at Stifel forum: pipeline bets and cash runway - Investing.com
Odyssey Therapeutics, Inc.(NasdaqCM: ODTX) added to S&P Global BMI Index - marketscreener.com
Odyssey Therapeutics, Inc.(NasdaqCM: ODTX) added to Russell 3000 Growth Benchmark - marketscreener.com
Odyssey Therapeutics to Participate in Stifel 2026 Virtual Immunology and Inflammation Forum - GlobeNewswire
A biotech presentation is set for Sept. 23. Odyssey Therapeutics will take part online. - Stock Titan
Odyssey Therapeutics (ODTX) Banks Two More Years As Trials Multiply - Yahoo Finance
Odyssey Therapeutics, Inc. Common Stock (NASDAQ: ODTX) Stock Price, News & Analysis - kalkine.ca
Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Odyssey Therapeutics’ OD-001 Meets Key Endpoints in Ulcerative Colitis Trial - Minichart
symbol__ Stock Quote Price and Forecast - CNN
Oral ulcerative colitis drug at Odyssey (ODTX) put 27% of patients in remission—larger trials are planned - Stock Titan
Odyssey Therapeutics posts September 2026 presentation detailing OD-001 Phase 2a success, $433M cash runway into H2 2028 - TradingView
ODTX Price Today: Odyssey Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC
RIPK2 inhibitors reported in Odyssey Therapeutics patent - BioWorld News
Odyssey Therapeutics Hits $900M Valuation In Nasdaq Debut, Stock Climbs 13% Before Diving Lower - Stocktwits
Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases - Eastern Progress
Q3 Earnings Forecast for ODTX Issued By HC Wainwright - MarketBeat
Odyssey Therapeutics to Participate in Upcoming Investor Conferences - Moomoo
HC Wainwright Initiates Odyssey Therapeutics at Buy With $44 Price Target - Yahoo Finance
Odyssey Therapeutics (ODTX) Stock Trends and Sentiment 2026 - marketbeat.com
J.P. Morgan Maintains Odyssey Therapeutics(ODTX.US) With Buy Rating, Raises Target Price to $29 - Moomoo
Odyssey Therapeutics (ODTX) Looks Fully Valued As Earnings And Evotec Deal Refocus Attention - Yahoo Finance
Odyssey Therapeutics (ODTX) Stock Looks Reasonable As AI Research News Lands - Sahm
Odyssey Therapeutics Ord Shs (Proposed) (ODTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Evotec and Odyssey Forge AI-Powered Drug Discovery Pact Targeting Autoimmune Diseases - finance.biggo.com
Odyssey Therapeutics (NASDAQ:ODTX) Given New $29.00 Price Target at JPMorgan Chase & Co. - MarketBeat
EQS-News: Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases - sharewise.com
Odyssey Therapeutics: Q2 Earnings Snapshot - marketscreener.com
Odyssey Therapeutics, Inc. Q2 2026: Revenue $0 EPS $(1.74) — 10-Q Summary - TradingView
Biotech Stocks At 52-Week HighsBVS, TVTX, ODTX, CRL Climb With Q2 Results, ACRS - RTTNews
Evotec and Odyssey Pair AI With Lab Tests for Immune Diseases - Stock Titan
Evotec Se and Odyssey Therapeutics, Inc. Enter Ai-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases - marketscreener.com
Evotec : and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases - marketscreener.com
Odyssey Therapeutics (ODTX) Institutional Ownership 2026 - MarketBeat
Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Odyssey Therapeutics reports Q2 2026 net loss $52.8M; cash $433.1M to fund into 2H 2028 - TradingView
Odyssey Therapeutics, Inc. Revenue Breakdown – NASDAQ:ODTX - TradingView
ODTX|Odyssey Therapeutics Ord Shs (Proposed)|Price:18.660|Chg%:+0.990 - TradingKey
Odyssey Therapeutics (ODTX) Earnings Date and Reports 2026 - MarketBeat
Enterprise value to EBITDA forward of Odyssey Therapeutics, Inc. – NASDAQ:ODTX - TradingView
Enterprise value to revenue forward of Odyssey Therapeutics, Inc. – NASDAQ:ODTX - TradingView
Finanzdaten der Odyssey Therapeutics Inc-Aktie (ODTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):